Trials / Terminated
TerminatedNCT02229266
Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML
Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With Haploidentical Natural Killer Cells in High-risk Acute Myeloid Leukemia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Technische Universität Dresden · Academic / Other
- Sex
- All
- Age
- 60 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The trial investigates the efficacy of adoptive immunotherapy with haploidentical natural killer cells compared to standard chemotherapy (after first complete remission) in patients with a high-risk acute myeloid leukemia being older than 65 years of age and not eligible for allogeneic transplantation
Detailed description
Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NK cells | |
| DRUG | Cytarabine | 1 cycle of consolidation chemotherapy with high-dose cytarabine |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2017-04-22
- Completion
- 2017-04-22
- First posted
- 2014-09-01
- Last updated
- 2021-08-16
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02229266. Inclusion in this directory is not an endorsement.